000			02259cam a2200409Mu 4500
001			ocn779141401
003			OCoLC
005			20240729130942.0
006			m d
007			cr |n|
008			120305s2012 xx o 000 0 eng d
040			_aEBLCP _beng _cEBLCP _dOCLCQ _dN$T
020			_a9781608052974 (electronic bk.)
020			_a1608052974 (electronic bk.)
035			_a(OCoLC)779141401
035			_a500767 _b(N$T)
072		7	_aHEA _x039030 _2bisacsh
072		7	_aMED _x062000 _2bisacsh
049			_aN$TA
100	1		_aPodar, Klaus.
245	1	0	_aMultiple Myeloma - A New Era of Treatment Strategies _h[electronic resource].
260			_aSharjah : _bBentham Science Publishers, _c2012.
300			_a1 online resource (217 p.)
505	0		_a01 Multiple Myeloma -- A New Era of Treatment Strategies.pdf; 02 Cover Page; 03 REVISED eBooks End User License Agreement-Website; 04 TABLE OF CONTENTS; 05 Foreword; 06 PREFACE; 07 Contributors; 08 Section 1; 09 Chapter 01; 10 Chapter 02; 11 Chapter 03; 12 Section 2; 13 Chapter 04; 14 Chapter 05; 15 Chapter 06; 16 Chapter 07; 17 Chapter 08; 18 Section 3; 19 Chapter 9; 20 Chapter 10; 21 Chapter 11; 22 Section 4; 23 Chapter 12; 24 Chapter 13; 25 INDEX.
520			_aMultiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and immunodeficiency. It is now well established that MM cell- induced disruption of the bone marrow homeostasis between the highly organized cellular and extracellular compartments supports MM cell proliferation, survival, migration, and drug resistance via activation of various signaling pathways. Based on this knowledge, the prototypic drugs thalidomide, bortezomib, and lenalidomide, which target both MM cell.
588			_aDescription based on print version record.
650		4	_aMultiple myeloma. _97046
650		4	_aMedicine.
650		0	_aMultiple myeloma _xTreatment.
700	1		_aAnderson, Kenneth C.
856			_u#gotoholdings _yAccess resource
938			_aEBL - Ebook Library _bEBLB _nEBL864207
938			_aEBSCOhost _bEBSC _n500767
910			_acpp1723AUTO
942			_n0
994			_a02 _bN$T
999			_c90786 _d90786